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The mesangial cell is surrounded by a pericellular matrix
(MM), the composition of which helps to determine the physi-
cal, mechanical and functional properties of the glomerulus.
This highly specialized matrix, like the glomerular basement
membrane (GBM), is composed mainly of type IV collagen,
laminin and heparan sulphate proteoglycan. In addition, and in
contrast to the GBM, the MM also contains significant amounts
of fibronectin and chrondroitin sulphate proteoglycan. Under
normal physiological conditions these matrix components, as
with the components of other connective tissues, are continu-
ally being synthesized and degraded, albeit at different rates. In
the healthy glomerulus the controlled activity of the mesangial
cell is thought to account for both MM synthesis and degrada-
tion, and furthermore is involved in the remodelling of the
GBM. These processes appear to be tightly regulated since the
integrity of both glomerular matrices are strictly maintained in
the adult animal. Uncontrolled metabolism of the MM and
GBM, however, does occur and a common feature in most
forms of chronic renal disease is the development of sclerosis
which is particularly marked within the mesangial space. This
suggests that in the mesangial cell the mechanisms responsible
for the turnover of matrix are no longer coordinated.
Current views suggest that degradation of the extracellular
matrix (ECM) is a two step process with initial enzymatic or
physical disruption (such as, oxygen radical damage) in the
extracellular space followed by endocytosis of the partially
degraded components and subsequent digestion by lysosomal
proteinases such as cathepsins B, L and D. The serine and the
metalloproteinases are most likely to play a critical role in the
first stage since they are active at neutral pH and are secreted
by cells at the appropriate site. This review summarizes the
biochemical properties of tissue proteinases, with particular
emphasis on the recent advances of the functional properties
and control of the matrix neutral metalloproteinases (MMPs),
and indicates their involvement in renal pathology. Since this
review is brief and somewhat arbitrarily selective, only recent
key papers and reviews are included.
Tissue proteinases
In higher animals the endopeptidases are represented by four
evolutionary or superfamilies of enzymes related to chymo-
trypsin, papain, pepsin and thermolysin, and which are referred
to as aspartic, cysteine, serine and metallo-type proteinases,
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respectively (Table 1). Although examples of each class can
degrade matrix molecules, those thought to be principally
involved are the MMPs and the serine proteinases of the
plasminogen/plasmin cascade.
Aspartic
Asparate proteinases contain two aspartic residues at their
active center and are specifically inhibited by pepstatins. Ca-
thepsin D is an ubiquitous glycoprotein found in the lysosonies
and is involved in intracellular metabolism of endocytosed
proteins but can also degrade articular cartilage or GBM.
Cysteine
The cysteine proteinases cathepsins B, L, N and S are
synthesized as larger proforms and subsequently processed to
their lysosomal forms (Mr 20 to 30 K). They depend on a
reduced thiol group at their active site for hydrolytic activity,
are activated by metal chelators and inhibited by alkylating
reagents and specifically by cystatins. In vitro studies have
shown that cathepsins B and L degrade matrix proteins such as
type I collagen, laminin and proteoglycans at acid pH. These
properties suggest that their role in the degradation of matrix
components is likely to be an intracellular one within phagoly-
sosomes. However, it has been proposed that a low pH
generated in a restricted extracellular space may allow these
proteinases to act outside the cell. Cathepsin B can activate
latent collagenase and so may have an indirect role in ECM
metabolism.
Serine
The serine proteinases contain a uniquely reactive serine side
chain at the active center and are inhibited by diisopropyl
fluorophosphate and serpins. These enzymes are active at
neutral pH, require activation and are located either in the
extracellular milieu [for example, plasminogen activator (PA)]
or in polymorphonuclear leucocyte (PMN) intracellular gran-
ules (such as, elastase and cathepsin G). Plasmin (generated
from plasminogen by PAs) and the PMN serine proteinases are
active against proteoglycans, collagen telopeptides and GBM (a
source of insoluble type IV collagen).
Metalloproteinases (MMPs)
The tissue MMPs constitute an important family of structur-
ally and functionally homologous metal-dependant proteinases
which play an important role in the degradation of the compo-
nents of the ECM (Table 2). The substrate specificity of these
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Table 1. Major classes of proteinases
Class (Family) pH Optima Exampl&' Inhibitor(s)
Aspartic (Pepsin) 3—5 Cathepsin D Pepstatin
Cysteine (Papain) 3—8 Cathepsin B
I Cathepsin L
a2M
a2M
Cystatins
(leupeptin)
E-64
Serine (Chymotrypsin) 6—9 Thrombin a2M
Plasmin PAl
tPA Aprotinin
uPA PMSF
I—-s;--I
Cathepsin G I
Metalloproteinases (Thermolysin) 6—9 Collagenase
Gelatinase
a2M
TIMP
LIMP
Stromelysin Metal chelators
Collagenase
Gelatinase
a Enzymes located within lysosomes (LI) or in PMN granules (iJ)
Table 2. Matrix metalloproteinases and their major substrates
Collagen type Gelatin type
PG FN Lam GBMEnzyme (Mr) I III IV V VII I III IV V
PMN collagenase (75 K) + + — — + (+) (+) (+) — —
Collagenase (52 K) + + — — + (+) (+) (+) — — — — —
PMN gelatinase (92 K) — — + + — + + + + — +
Gelatinase (72 K) — — + (+) — + + + + — — — +
Stromelysin-l (53 K) — + + + ND ± + + + + + + +
Stromelysin-2 (53 K) — + + + ND + + (+) + + + + ND
Stromelysin-3' ND ND ND ND ND ND ND ND ND ND ND ND ND
PUMP-I (28 K) — — — — ND + + ± + +_—- + + ND
The list is not complete and contains mainly components relevant to the glomerular ECM. Lack of activity by an enzyme against a substrate is
indicated by —, good activity by a +, slight activity by a (+) and not determined by ND. Abbreviations are: FN, fibronectin; PG, proteoglycan;
Lam, laminin.
a Existence based on the sequence of gene expressed in human breast carcinomas
neutral proteinases varies considerably, In general they exhibit
poor peptidase activity and are involved in specific cleavage at
Gly-X bonds where X is usually a hydrophobic amino acid (Leu
or lie) present in large proteins such as those located in the
ECM. In mammalian cells, this gene family includes both
fibroblast and PMN types of interstitial collagenase, two types
of gelatinase (or type IV collagenases) referred to as PMN or 92
K gelatinase, fibroblast or 72 K type, at least three stromelysins
and a truncated metalloproteinase (PUMP-I) which lacks the
C-terminal domain present in other MMPs. These enzymes, all
of which have been cloned, share several common features: (i)
they are capable of degrading at least one component of the
ECM; (ii) they are optimally active at neutral PH; (iii) they have
an absolute requirement for Zn2; Ca2 ion also required for
stabilization of these proteins although the molecular basis for
this requirement is not known; (iv) metal chelating agents such
as EDTA and I ,1O-phenanthroline block their activity but this
inhibition can be reversed by the addition of exogenous Zn2;
(v) they are secreted in an inactive proform and activated by the
extracellular milieu; and (vi) they are all inhibited by specific
Fig. 1. Consensus of the amino acid sequences of human MMPs and their domain structures. The sequences can be divided into three domains;
the propeptide (domain I) cleaved on activation and which contains the highly conserved sequence PRCGVPDV; a catalytic domain (domain II)
which contains a putative Zn2 binding motif HEXGH; a disulphide-bonded C-terminal domain (domain III) with sequence similar to hemopexin
and vitronectin. The 72 K and the 95 K both contain an extra sequence with similarities to the collagen binding domain of fibronectin(FN-tIl). In
addition, the 95 K gelatinase contains an insert with sequences similar to a2-chain of type V collagen. PUMP-l lacks the C-terminal domain. The
consensus was kindly provided by Dr. JJ. Reynolds, Strangeways Research Laboratory, Cambridge and is reproduced with permission.
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Ht_imr Mt1 1
1 Stromelysin-i 3 PUMP-i 5 PMN Collagenase 7 72 kDa Gelatinase
2 Stromelysin-2 4 Collagenase 6 MMP 11 (SL—3) 8 95 kDa Gelatinase
I PrDpeptid I
Latency
I VP. LDGAARGEDTS.t4NL. . . .VQKVLENYYDLEKDVKQ. FVRRK. DSGPVV. KKIREMQKFLGLEVTGKIDSDTLEVMRKI'KujywI)VGH
2 VP. LSGAAKEED.SNKDL. . . .AQQYLEKYYNLEKDVKQ. F. RRK. DSNLIV. KKIQGMQKFLGLEVTGKLDTDTLEVMRKPRCGVPDVGH
3 LP. . LP.QEAGGMS. . ELQWEQAQDYLKRFYL YD. SETK. .NANSLE.AKLKEMQKFFGLPITGMLNSRVIEIP4QKPRCGVpDVAE
4 FPA.TLETQEQDV. . . DL.. . .VQKYLEKVYNLKNDGRQ.VEKRR.NSGPVV. EKLKQMQEFFGLKVTGKPDAETLKVMKQPRCGVPDVAQ
5 FPVSSKEK NTKT VQDYLEKFYQLPSNQYQ. STRK. . NGTNVIVEKLKEMQRFFGLNVTGKPNEETID14MKKPRCGVPDSGG
6 LPP DV HHL HAERRGPQPWH. .AAL. . PSSPAPAPATQEA.PRPASSLRPPRCGVPDPSD
7 APSPIIKFPG. DVAPKTDKELAV.QYLNTFYGCPKESCNLFVLK. . DT LKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVAN
8 APRQRQSTLVLFPGDLRT.NLTDRQ. LAEEY. LVRYGVTRVAEI4RGESKSLG. PALLLLQKQLSLPETGELDSATLKAHRTPRCGVPDLGR
j*insert for t4MP 11: GLSARNRQKR
FCata1ytic Domain
1 FRTFPGIPKWRKTHLTVRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLVEGEADIMISFAVREHGDFVPFDGPGNVLAH
2 FSSFPGMPKWRKTHI.TVRIVNYTPDLPRDAVDSAI EKALKVWEEVTPLTFSRLYEGEADIMISFAVKEHGDFYSFDGPGHSLAH
3 VSLFPNSPKWTSKWTVRIVSYTRDLPHITVDRLVSKALNMWGKEI PLHFRKVVWGTADDIIGFARGAHGDSYPFDGPGNTLAH
4 FVLTEGNPRWEQTHLTVRI ENVTPDLPRADVDHAI EKAFQLWSNVTPLTFTKVSEGQADIMISFVRGDHRDNSPFDGPGGNLAH
5 FMLTPGNPKWERTNLTVRIRNYTPQLSEAEVERAIKDAFELWSVASPLIFTRISQGEADINIAFVQRDHGDNSPFDGPNGILAH
6 FVLSGG. .RWEKTDLTVRILRFPWQLVQEQVRQTP4AEALKVWSDVTPLTFTEVHEGRADIP4IDFARYWHGDDLPFDGPGGILAH
7 YNFFPRKPKWDKNQITYRI IGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGDGYPFDGKDGLLAH
8 FQTFEGDLKWHHHNITVWIQNVSEDLPRAVIDDAFARAFALWSAVTPLTFTRVVSRDADIVIQFGVAEHGDGVPFDGKDGLLAH
Zn••
1 AVAPGPGINGDAHFDDDEQWTK. DTTGTNLFLVAA. HEIGHSLGLFHSANTEALHVPLYHSLTDLTRFRLSQDDINGIQSLYG
2 AYPPGPGLVGDIHF000EKWTE. DASGTNLFLVAA. HELGHSLGLFHSANTEALMVPLYNSFTELAQFRLSQDDVNGIQSLVG
3 AFAPGTGLGGDAHFDEDERWTDGSSLGIN. FLVAATHELGHSLGP4GHSSDPNAVMYPTVGN. GDPQNFKLSQDOIKGIQKIVG
4 AFQPGPGIGGDAHFDEDERWTN. NFREYNLHRVAA. HELGHSLGLSHSTDIGALMVPSYT. FSGDVQ. . LAQDDIDGIQAIVG
5 AFQPGQGIGGDAHFDAEETWTNTSA. NYNLFLVAA. HEFGHSLGLAHSSDPGALtIYPNYA. FRETSNYSLPQDDIDGIQAIYG
6 AFFPKTHREGDVHFDVDETWTIGDDQGTDLLQVAA. HEFGHVLGLQHTTAAKALP4SAFYT. FRYPL. . SLSPDDCRGVQHLYG
7 AFAPGTGVGGDSHFDDDELWTLGEGQGYSLFLVAA.HEFGHAMGLEHSQDPGALI4APIVT.YT. K. NFRLSQDDIKGIQELYG
8 AFPPGPGIQGDAHFDDDELWSLGKGVGVSLFLVM. HEFGHALGLDHSSVPEALNVPMYR. FTEGPP. - LHKDDVNGIRHLYG
Inserts for 72 kDa and 95 kDa cielatinases (3 repeats)
7 VVRVKY. GNADGEYCKFPFLFNGKEYNSCTDTRSDGFt.wcSTTYNFEKDGKYGFcpHE
8 VVPTRF. GNADGAACHFPFIFEGRSVSACTTDGRSDGLPWCSTTANVDTDDRFGFCPSE
7 ALF1 . I4GGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDVDRDKKVGFCPET
8 RLYTRD. GNADGKPCQFPFI FQGQSYSACTTDGRSDGYRWCATTANVDRDKLFGFCPTR
7 AMSTV. GGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKJ4WCATTANVDDDRKWGFCPDQ
8 ADSTVr4GGNSAGELCVFPFTFLGKEYSTCTSEGRGDGRLWCATTSNFDSDKKWGFCPDQ
C Terminal Domain
1 PP. PD. .SPETP. LVPTEPVPpEpGT. PAN CDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLE. PELHL. IS.SFWPS
2 PP. P.A.STEEP. LVPTKSVPSGSEM.PAK CDPALSFDAISTLRGEYLFFKDRYFWRRSHWNPE. PEFHL. IS.AFWPS
3 .KR. . . .SNSRKK
4 . .R.. . .SQN PVQPI. .GPQT.PKA CDSKLTFDAITTIRGEVt4FFKDRFVMRTNPFVPE.VELN.FIS.VFWPQ
5 1 SSN PIQPT. .GPST. PKP CDPSITFDAITTLRGEILFFKDRVFWRRHP.QLQRVEI4N. FISL. FWPS
6 QPWPTVTSRTPALG. P.QAGIDTNEIAPLEPDAPPDACEA. .SFDAVSTIRGELFFFKAGFVWRLRGGQLQ. PG.YPALASRHWQG
7 .ASPDID. . . LGTG. PT. PTL .GPVT. PEI CKQDIVFDGIAQIRGEIFFFKDRFIWRTVTPR. DKPMGPL. LVATFWPE
8 TAGP. . .ST. .ATTVPL SPV DDACNVNI.FDAIAEIGNQLVLFKDGKYWRFSEGRGSRPQGP.FIIADKWPA
PRPEPEPRPPTTTTPQPTAPPTvCPTGPP VHPSERPTAGPTGPPSAGPTGPP j
Insert for 95 kDa 2elatinase
1 LPSGVDAAVEVTSKDLVFIFKGNQFWAIRGNEVRA. GYPRGIHT. 1G. . . FPPTV.RKIDAAISDK. EKNKTYFFVEDKVWRFDE
2 LPSYLDAAYEVNSRDTVFIFKGNEFWAIRGNEVQA. GVPRGIHT. LG. . - FPPTI .RKIDAAVSDK.EKKKTVFFAADKYWRFDE
4 LPNGLEAAVEFADRDEVRFFKGNKYWAVQGQNVLH.GYPKDIYSSFG. . . FPRTV.KHIOAALSEE.NTGKTYFFVANKVWRVDE
5 LPTGIQAAVEDFDRDLIFLFKGNQYWAL$GVDILQ. GVPKDI .SNYG.. .FPSSV.QAIDAAVFVRS.. .KTVFFVNDQFWRVDN
6 LPSPVDAAFEDAQGH. IWFFQGAQVWVYDG. EKPVLG. PAPL. TELGLVRFP. .V.H. . .AALVWGPEKNKIVFFRGRDVWRFHP
7 LPEKIDAVYEAPQEEKAVFFAGNEVWIYS.ASTLERGVPKPL.TSLGL. .PP. DV.QRVDAA. FNWSKNKKTYIFAGDKFWRYNE
8 LPRKLDSVFEEPLSKKLFFFSGRQVWVVTGASVL. .G. PRRL. DKLGLGA. - - DVAQ.VTGAL. .RSGRGKMLLFSGRRLWRFDV
1 KRNSMEPGFPKQIAEDFPGIDSKI .DAVFEE. FGFF.VFFTGSSQLEFDp. -
. .NAKKVTHTLKSNS. .WLNC
2 NSQSMEQGFPRLIADDFPGVEPKV. DAVLQA. FGFF. YFFSGSSQFEFDP.. . .NARMVTHILKSNS. .WLHC
4 YKRSMDPGYPKMIAHDFPGIGHKV.DAVFMK. DGFF.VFFHGTRQYKFDP. KIK. .RIL.TIQKANS. .WFNCRKN
5 QRQFMEPGVPKSISGAFPGIESKV. DAVFQQ. EHFF. HVFSGPRYYAFOLI. .
- AQRVT.RVARGNK. .WLNCRYG
6 STRRVDSPVPRR. ATDWRGVPSEI. DAAFQDAOGYA. VFLRGRLYWKFDPvKVKALEGFPRLVGPD. .
- FFGCAEPANTFL
7 VKKKtIDPGFPKLIADAWNAIPDNL. DAVVDLEGGGIISYFFKGA. YV. . .1. KLENQSLKSVKFGSIKSDWLGC
8 KAQMVDPRSASEVDRMFPGVPLDTf4D. VFQVREK. A. VFCQDRFYWRVSSRSELNQVDQVGVVTVD. . . ILQCPED
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tissue inhibitors of metalloproteinases (TIMP). Inspection of
the amino acid sequences of the cloned MMPs reveals a high
degree of conservation both across enzyme types (55% homol-
ogy between interstitial collagenase and stromelysin-l) as well
as across species (75% between human, rat and rabbit strome-
lysin). This sequence similarity can be divided into several
domains (Fig. 1). The pro- (or latent) enzyme consists of three
separate regions: (i) the amino-terminal propeptide region (do-
main I); (ii) a catalytic domain (domain II); and (iii) a C-terminal
domain (domain III). Not shown in Figure 1 is the putative
hydrophobic leader peptide which targets the enzyme for
secretion but is subsequently lost and is absent from the
secreted latent enzyme. Domain I contains the highly con-
served sequence PRCGVPDV which is cleaved when the
MMPs are activated. The actual active enzyme is a two domain
protein made up of a "catalytic" domain (domain II) and a
disulphide bonded C-terminal domain (domain III). Domain II
contains the putative Zn2-binding region and the active site.
This region has conserved histidine residues (HEXGH) and has
significant homology with part of the zinc-binding region lo-
cated in the bacterial metalloproteinase thermolysin. Domain
III is usually referred to as the vitronectin-like domain (he-
mopexin family). The function of this domain is little under-
stood, but it may represent a region that recognizes a matrix
receptor and thus is involved in substrate specificity.
Based on the above amino acid sequence homology, intersti-
tial collagenase and stromelysin are more closely related to
each other than to the gelatinases. In the two gelatinases the
domain II contains unique region of 175 residues organized into
three 58-residue head-to-tail repeats with significant homology
to the type II motif of the collagen-binding domain of fi-
bronectin. The 95 K type gelatinase has a further insertion with
some homology to the a2-chain of type V collagen.
Substrate specificity of metalloproteinases
Co/la genases
The collagenases hydrolyse all three a chains of types I, II
and III collagen at a specific locus located one quarter length
from the C-terminus. The a1(I)chains are cleaved at the Gly-Ile
residue (amino acids 775-776) and the a2(I)chain at a Gly-Leu
residue in the homologous region. Collagens II and III are
cleaved in a similar manner. Interestingly, although the same
bonds occur elsewhere in the collagen molecule they are not
hydrolyzed. After cleavage by collagenase the molecules lose
their helical structure and become susceptible to further degra-
dation by gelatinases and other 'non-specific' proteinases. In
addition, the interstitial collagenases hydrolyze native type VII
and X collagens. More recent data indicate that these enzymes
may have a broader specificity than at first believed.
Two distinct types of interstitial collagenases have been
identified. The first is produced by human skin, synovium and
gingival fibroblasts, keratinocytes and monocytes (usually re-
ferred to as human fibroblast collagenase) while the other is
from human PMNs. The human fibroblast collagenase is a latent
enzyme of Mr 52 K with a minor glycosylated form of Mr 59 K,
which on activation are reduced to molecules of Mr 42 and 48
K, respectively. Human PMN collagenase, which is stored in
the specific granules, has a Mr of 75 K. These forms have also
been reported to differ from each other immunologically and in
substrate preferment, indicating that tissue differences in this
class of MMPs exist. The catalytic rates for collagen degrada-
tion for the PMN collagenase are in the order type I > II> HI
compared to fibroblast collagenase, III> I > II. During the last
year the cDNA encoding for PMN collagenase has been iden-
tified and sequenced. The analysis of the deduced protein
confirmed that PMN collagenase is a distinct protein from
fibroblast collagenase.
Gelatinases (type IV co/la genases)
These MMPs bind tightly to and degrade all denatured
collagens (gelatins) and thus together with specific collagenase
are thought to play an important role in interstitial collagen
turnover. Two major types of gelatinases, the products of
different genes have been described to date. In general PMNs
and monocytes/macrophages secrete a large Mr (95 K) glyco-
sylated species, whereas a progelatinase of approximately Mr
72 K (mainly non-glycosylated) is secreted by many connective
tissue cells. In addition, gelatinases of both types have been
identified from the culture medium of several cells of neoplastic
origin and from transformed fibroblasts and epithelial cells.
Although these gelatinases have not been fully characterized it
is likely that they are similar, if not identical, to the 95 K and 72
K species derived from normal cells.
Both the 95 K and the 72 K forms of gelatinase appear to have
identical substrate specificity cleaving type IV collagen into
C-/4 and N-¼ fragments, native type V, VII and X, elastin and
denatured collagens of all genetic types. They do not hydrolyze
laminin or fibronectin and only have limited activity against
casein, that is, they have limited stromelysin activity. Thus the
substrate specificity of matrix gelatinases, especially their abil-
ity to cleave native type IV and type V collagens suggests that
they may play a pivotal role in the destruction of basement
membranes. Indeed, both forms of gelatinase can in vitro
release soluble hydroxyproline from insoluble type IV collagen,
the principle protein found in basement membranes. However,
the relevance of this observation to the in vivo turnover of
basement membrane has been recently questioned. For exam-
ple, Lyons et al demonstrated that the rate of cleavage of native
type IV and type V collagen by a human mammary carcinoma
cell-derived 95 K gelatinase is relatively low, certainly much
lower than the cleavage rate calculated for the hydrolysis of
interstitial collagen by collagenase. In a separate study MacKay
et a! showed that a 65 K and 92 K gelatinase purified from
several human tumor cell lines showed limited ability to hydro-
lyze native full lengths of EHS type IV collagen when examined
under conditions (below 20°C) which did not denature the
collagen substrate. In contrast, EHS type IV collagen degrada-
tion was obtained above 30°C but did not yield fragments of 3/4
and ¼ as shown for other MMPs of similar molecular weight.
These results clearly differ from the accepted idea that gelati-
nases (those derived from normal tissue) degrade native type IV
collagen at a specific locus. The above observation concerning
the exact specificity of gelatinases is important since it infers
that tumor cell gelatinases may play a secondary role to a
telopeptide degrading enzyme(s) to secure the required base-
ment membrane degradation necessary for tumor metastasis, If
upheld then it poses the question as to the identity of the
proteinase involved in the initial cleavage of the basement
membrane collagen. As discussed below, stromelysin is a
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possible candidate but proteinases other than MMPs, such as
plasmin, could be involved.
Stromelysins
The name stromelysin has been given to MMPs with a broad
substrate specificity and which originate from stromal cells and
is to be preferred to the terms proteoglycanase and caseinase
previously found in the literature. Three gene products have
been identified and extensively characterized: stromelysin-i,
stromelysin-2, and PUMP-i. In addition, a new metalioprotein-
ase gene with homology to stromelysin-l and -2 has been
identified that is expressed in stromal cells of breast carcino-
mas. Stromelysin-l is isolated from human synoviai fibroblasts
in a latent form (Mr 55 K) which can be converted into an
enzymatically active enzyme (Mr 41 K) by treatment with
trypsin or organomercurials, Transin is the rat equivalent of
stromelysin-l. Stromelysin-2 is a related but distinct protein to
stromelysin-i and is associated with malignant tumors.
Stromelysin-i and -2 show 79% sequence similarity. The sub-
strate recognition by the two enzymes is also very similar with
the one difference being that stromelysin-2 has only limited
activity against denatured type IV collagen (Table 2). In addi-
tion to their potential to degrade matrix components, strome-
lysin- 1, stromelysin-2 and transin activate procollagenase in
vitro. The final member of this group of MMPs is a truncated
version of stromelysin which has been named PUMP-I (puta-
tive metalloproteinase) because its existence was deduced from
the sequence of a cDNA clone obtained by low stringency
screening of a mixed cDNA library with transin. From the
amino acid sequence data it was deduced that PUMP-i lacked
the C-terminal hemopexin-like domain (domain III). Expression
of PUMP-l cDNA in Cos cells using the expression vector
pKCR3 results in the secretion of a latent organomercurial-
activatable proteinase detectable by using type I gelatin and
casein, a combination of substrates routinely employed for the
assay of stromelysin. The estimated Mr of the active proteins
(Mr 21 K and 19 K) were in good agreement with the predicted
Mr from the cDNA sequence. The characteristics of rPUMP-1
such as latency, activation with organomercurials, and inhibi-
tion by TIMP or metal chelators confirmed that it belongs to the
MMP family. In addition to these properties, PUMP-i was
capable of degrading various connective tissue matrix mole-
cules (Table 2), suggesting that it is related to stromelysin rather
than collagenase or gelatinase.
Regulation of metalloproteinases
It is evident from the above discussion that MMPs can
collectively catabolize all the major constituents of the ECM
and as such play major roles in the remodelling events that
occur in normal morphogenesis, wound healing and uterine
resorption. It is not surprising, therefore, that a number of
control mechanisms appear to regulate their activities. These
mechanisms operate at several levels and include their synthe-
sis and secretion, activation in the extracellular milieu before
the substrate can be degraded, and inhibition by the stoichio-
metric complexing of the activated enzyme with natural inhib-
itors such as TIMP (Fig. 2).
The synthesis and secretion of pro-MMPs and TIMP are
regulated by several cytokines, polypeptide growth factors and
hormones, as well as phorbol ester (TPA) (Table 3). IL-l/3 and
TNFs are among the most potent inducers, a finding which
appears to be universally true for mesenchymal cell types and
monocytes/macrophages. This has been shown both at the level
of gene transcription and by the incorporation of labelled amino
acids into collagenase and stromelysin protein precipitated with
specific antiserum. Although few studies have critically inves-
tigated how cytokines and growth factors regulate the balance
of expression between metalloproteinases and inhibitor, the
evidence to date suggests that the production of these proteins
is not co-ordinately expressed, a finding which is likely to be
critical in controlling their net effect on ECM catabolism. The
interplay between the different cytokines and growth factors is
further highlighted by the finding that TGF-f3 blocks both
EGF-induced MMP and plasminogen activator synthesis. In
addition cytokines have many effects on target cells besides the
enhancement of MMP and TIMP synthesis. Thus IL-i and TNF
both induce IL-6 synthesis, suggesting that a role for IL-6 in
matrix re-modelling is the upregulation of TIMP to counter
balance the catabolic effects of IL-i and TNF. IL-i also
enhances the synthesis and release of PGE2 by mesenchymal
target cells such as synovial fibroblasts and articular chrondro-
cytes. Since PGE2 upregulates procollagenase synthesis the
response of the target cells to IL-i and TNF may, in part, be
mediated through an increase PGE2 production. In human
chondrocytes indomethacin had no effect on the synthesis of
latent enzyme or the cellular levels of procollagenase mRNA
induced by rIL-l$. However, in other cells it appears that
inhibition of PGE2 synthesis may be accompanied by reduced
levels of collagenase in culture medium.
The mechanism by which MMP gene transcription is modu-
lated by IL-l, TNF and PDGF involves the binding of the
nuclear transcription factors FOS and JUN to an enhancer
element, the so-called TPA responsive element (TRE) or acti-
vator protein-i (AP-l) binding site. The mechanisms of action
of TGF-/3 also involves FOS protein, but in this case the nuclear
protein binds to a TGF-f3l inhibitor element (TIF).
A second way of controlling matrix turnover by MMPs is at
the level of conversion of the proenzymes to their active forms.
Most information on this step has come from studies on the
activation of procollagenase, but the data probably applies to
other members of the MMP family. Activation of the 52 K
proenzyme in vitro can be accomplished by several physical
and chemical agents, all of which generate a 42 K active
enzyme. Organomercurials activate the latent form by causing a
conformational change involving a cysteine-zinc interaction and
free the zinc to participate in an intramolecular autolytic
reaction. Trypsin initially cleaves the Arg36-Asn37 bond in
domain I to generate a 46 K inactive form which in turn is
activated autocatalytically by hydrolysis of one of the bonds
situated between domains I and II. However, several reports
indicate that the activity attained by these treatments is not
maximal and could be greatly enhanced by the addition of
purified stromelysin. Furthermore, treatment of the 42 K form
by the same enzyme also caused a further decrease in Mr to
yield a 40 K peptide in which the collagenase activity was
significantly increased. Stromelysin alone did not fully activate
procollagenase but did induce changes similar to those obtained
with trypsin. Thus, it is apparent that activation of latent
collagenase requires both conformational changes and cleavage
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ECM degradation
Fragments
Fig. 2. Schematic presentation of factors influencing the extracellular activity of MMPs. The diagram is not intended to be comprehensive and
does not take into consideration the regulation of TIMP by cytokines or the superactivation of active collagenase by stromelysin. Other natural
inhibitors are also involved in the inactivation of active MMP such as a2—macroglobulin.
Table 3. Factors regulating MMP and TIMP expression
MMP TIMP
IL-i + +
TNF + +
PDGF + +
IL-6 +
TPA + +
FGF +
EGF +
TGF — +
Retinoids — +
Glucocorticoids — +ff ()b
a While TGF-/3 down regulates collagenase and stromelysin it slightly
up regulates gelatinase (see Overall et a!, 1989)b Relatively low effect
of critical bonds localized within domain I. Recent evidence
suggests that all the modes of activation of collagenase depends
on the dissociation of a complex formed between Cys73 in the
conserved PRCGVPDV sequence in domain I and the catalytic
Zn2 atom in domain II. The dissociation of this bond allows
the access of the water molecules necessary for the cleavage
mechanism to the active Zn2 site.
Activation of procollagenase is also achieved with cathepsins
B and L, PMN elastase and plasmin, any of which could
represent a physiologically relevant pathway of MMP activa-
tion. A role for plasmin is particularly attractive because
plasminogen activators are produced by macrophages, fibro-
blasts, and PMNs. Thus in a restricted space such as the
synovium, plasminogen could be activated to plasmin with
subsequent activation of collagenase or stromelysin. Plasmin
treatment of procollagenase generates the 42 K active form
which again requires the catalytic action of stromelysin for full
expression of activity. Based on these findings, a cascade of
proteolytic events has been proposed for the activation of
prometalloproteinases.
The third control of MMPs could occur with the down
regulation of enzyme activity through the interaction of natu-
rally occurring proteinase inhibitors such as a2-macroglobuiin
and TIMPs, of which at least two have been extensively
characterized. TIMP-l is a 28.5 K glycoprotein which forms a
stable complex with all activated MMPs. TIMP-2 is a smaller
SYNTHESIS
Up regulationIL-i; TNF; PDGF;
EGF; FGF
Plasminogen
activator
Down TGF; retinoids;
glucocorticoidsRegulation
Plasminogen
Plasn,in
CATH B or L
Clearance via
lysosomes
Latent MMP/*
ACTIVATION
TIMP
*
Active MMP __________ MMP-TIMPcomplex
INACTIVATION
1
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protein (21 K), is non-glycosylated and shows 70% homology to
TIMP-l. While both these proteins inhibit the active forms of all
three types of MMPs they differ in their interaction with latent
gelatinase. TIMP-l appears to selectively complex with the 95
K whereas TIMP-2 has a preference for the 72 K form. TIMP-l
and TIMP-2 are also regulated independently by TGF-f3, with
the latter down regulated and the former up regulated.
It has also been reported that collagenase gene expression
correlates with cell shape. Modulation of the morphology of
fibroblasts—both by chemical agents such as cytochalasin B or
TPA, and by the contraction of a collagen gel used as a culture
substrate—stimulates collagenase production. These results
indicate that the reorganization of the actin cytoskeleton of the
cell may modulate the metalloproteinase gene expression, and
hence the rate of matrix degradation.
Proteinases and glomerular matrix degradation
Serine and cysteine lysosomal proteinases
The potential role of the PMN serine proteinases in glomer-
ular matrix remodelling is also indicated by their substrate
specificity and in particular their ability to modify GBM.
Furthermore, immune histochemical studies of kidney treated
with elastase and cathepsin G shows extensive loss of laminin
from GBM. The observation that infusion of PMN elastase into
the renal artery results in proteinuria in rats also indicates that
proteinases may be directly involved in renal pathology. In
addition to the above biochemical data, several experimental
models, as well as clinical studies, support a role for PMN
proteinases in renal disease (for review see Baricos and Shah).
The main role of the cysteine proteinases in glomerular matrix
turnover is most probably linked to the lysosomal function of
mesangial cells, but as reviewed by Baricos there is evidence
that these acid proteinases may be involved with GBM pertur-
bation in glomerulonephritis.
Metalloproteinases
Mesangial cell proliferation and accumulation of mesangial
matrix are characteristic features of a variety of glomerular
diseases. It is widely accepted that the components of the
mesangial matrix are synthesized by the mesangial cells. More-
over, it is likely that the mesangial cells also regulate the
turnover of the constituent components of the matrix as well as
play a critical role in the removal or clearance of foreign
proteins deposited within the glomerulus. The matrix-degrading
specificity of proteinases, particularly the MMPs discussed
above suggest that in the normal glomerulus they may play a
central role in the processes that involve extensive mesangial
catabolism and remodelling. Recent studies by us have estab-
lished that actively cycling mesangial cells secrete a neutral
proteinase with gelatinase (type IV collagenase) activity. The
enzyme was secreted in a latent form, the active form of which
was shown to be a typical Zn2-dependent Ca2 activated
MMP with a neutral pH optimum. Biochemical characterization
indicated that the enzyme is a basic protein (p1 8.4) and
consisted of a protein doublet with Mr of 66 K and 68 K. Both
protein components were enzymatically active. The enzyme
degrades both soluble and insoluble basement membrane type
IV collagen, but does not specifically degrade types I, III or V
collagen or casein. However, it was able to degrade type V at
37°C where this collagen would be denatured and form gelatin.
The mesangial cells also secrete a protein identified as a
functional MMP inhibitor with biochemical and immunological
properties identical to TIMP- 1.
A polyclonal antibody was raised against the mesangial 66 K
protein band. This antibody in a Western blot recognized the
two protein bands at 66 and 68 K. Since these bands exactly
coincided with the bands of enzymatic activity obtained in
gelatin substrate gels, the two mesangial neutral proteinases are
immunologically related. Using this antibody the neutral pro-
teinase antigen was detected in almost all cultured mesangial
cells. In contrast the TIMP-antigen was expressed by fewer
than one-third of the mesangial cells. These findings suggest
that the synthesis of these two proteins may be independently
regulated. While little is known about the regulation of mesan-
gial cell TIMP, the gelatinase secretion appears to be enhanced
by macrophages and macrophage derived proinflammatory me-
diators. Thus co-culture of rat mesangial cells with elicited rat
peritoneal macrophages enhances the secretion of gelatinase
activity by as much as 30-fold. Crude macrophage conditioned
medium also induces an increase in neutral proteinase activity
of approximately 10-fold. Purified IL-l was also shown to
stimulate secretion of the enzyme, but to a lesser extent than
that obtained with either macrophage co-culture or with mac-
rophage conditioned medium. These findings suggest that while
IL-l enhances neutral proteinase synthesis, there is very likely
an interplay with other macrophage or autocrine-derived
growth factors which control the levels of this proteinase.
The recent report of Baricos and co-workers showing that
highly purified gelatinase (95 K) and stromelysin but not colla-
genase (52 K) degrade GBM extends the mesangial cell culture
data and further supports a putative role for MMPs in glomer-
ular pathophysiology. It also raises the question as to whether
mesangial cells synthesize and secrete collagenase and strome-
lysin. In the initial culture studies collagen and casein-degrading
activity were barely detectable. Very recent data from both
Northern and Western blot analyses using cDNA probes and
specific antisera to gelatinase (72 K), collagenase (52 K),
stromelysin-l and TIMP has confirmed the presence of the
fibroblast-type gelatinase and TIMP-l in human mesangial cells
and also demonstrated conclusively that these cells synthesize
and secrete collagenase. However, stromelysin was not de-
tected either as a message or protein.
Rat mesangial cells secrete a low amount of casein- and
proteoglycan-degrading activity with a Mr (estimated by gel
sieving) similar to stromelysin. Preliminary data has also been
obtained that human mesangial cells, following cytokine stim-
ulation, secrete a MMP with a Mr 30 K. Since these bands were
detected with gelatin and casein substrate gels the peptide
either represents an active fragment of stromelysin or is
PUMP-l. The Western blot of the partially purified proteinase,
probed with an antibody against the C-terminal of PUMP-l,
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identified a 30 K protein band identical in Mr to the caseinase
band obtained in the casein gel analysis (Marti, H-P, unpub-
lished data).
Recent experiments (Lovett, DH et al., unpublished data)
have utilized the mesangial cell polyclonal anti-gelatinase anti-
body to investigate the localization of this enzyme in intact
glomeruli. Light microscopic evaluation of normal rat cortex
demonstrated that the gelatinase antigen in vivo was limited
within the kidney to a small subset of intrinsic glomerular
mesangial cells with up to three positive cells per glomeruli per
section. At the immune-EM level antigen-gold complexes were
detected primarily in clusters at regions where the mesangial
cell directly abuts the overlying GBM. Trace amounts of TIMP
antigen were detected at the light histochemical level but
immunoelectron microscopy of this antigen revealed a diffuse
distribution within the mesangial matrix, and in addition was
observed in glomerular capillary endothelial cells. Further
localization data was obtained following the induction of acute
anti-Thy 1.1 glomerulonephritis. This demonstrated a time
dependent increase in the number of gelatinase-secreting
mesangial cells, which coincided with the development of
mesangial injury. In contrast to the proteinase, TIMP levels
were not changed. These results not only demonstrate for the
first time that in vivo a glomerular cell contains resting levels of
a MMP and its specific inhibitor. They also indicate that an
inappropriate expression of these proteins may contribute to
the progress of glomerular injury, or could be involved in the
matrix remodelling which accompanies this form of glomerular
injury.
Summary
The mesangial cell MMPs and their inhibitor may represent
proteins through which biological modifiers such as cytokines
and growth factors can control and influence the organization of
the glomerulus. At the present we can only speculate on their
exact function in glomerular disease. They could conceivably
play a role in glomerular conditions where mesangial hypercel-
lularity and cytoplasmic interposition between the endothelium
and the basement membrane are frequent occurrences, and in
which cytokine-enhanced synthesis of matrix-degrading en-
zymes could result in severe structural damage. A number of
glomerular diseases such as diabetic nephropathy are charac-
terized by the accumulation of glomerular matrix proteins. This
could be explained by the inappropriate expression of intrinsic
mesangial cell MMPs or TIMP. Further investigation of these
proteins in experimental models of glomerular disease or in situ
hybridization studies using the available probes promises to be
a rewarding area of research during the next few years. For
these studies the availability of rTIMP and recent developments
in the design of synthetic inhibitors of MMPs may allow more
searching investigations into the role of MMP in the pathophys-
iology of glomerular disease.
Reprint requests to Dr. Malcolm Davies, Institute of Nephrology,
University of Wales College of Medicine, Royal Infirmary, Cardiff, CF2
JSZ Wales, United Kingdom.
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